HALLE (SAALE), Germany, 11 October 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces that the […]
Probiodrug announces pricing of a EUR 14.9 million accelerated bookbuild offering of new shares HALLE/SAALE, Germany, 6 October 2016 – Probiodrug AG (the “Company“) (Euronext Amsterdam: […]
Probiodrug launches capital increase by means of an accelerated bookbuild offering HALLE/SAALE, Germany, 5 October 2016 – Probiodrug AG (the “Company“) (Euronext Amsterdam: PBD), a biopharmaceutical […]
HALLE (SAALE), Germany, 13 September 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announced today […]
In an acute peritonitis model PQ912 inhibits monocyte infiltration, increases eosinophils and enhances resolvin D2, an important lipid mediator which contributes to termination of inflammatory processes […]
HALLE (SAALE), Germany, 30 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announced its […]
Attendance at key conferences in September 2016 HALLE (SAALE), Germany, 25 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions […]
HALLE (SAALE), Germany, 23 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its results […]
Attendance at key conferences during August and September 2016 HALLE (SAALE), Germany, 16 August 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel […]